MOUNJARO 12.5 mg (Tirzepatide PFS) 12.5 mgx0.5 ml

Tirzepatide, the active ingredient in MOUNJARO 12.5 mg, activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, leading to improved glycemic control in patients with type 2 diabetes mellitus.

The usual dose of MOUNJARO 12.5 mg is determined by the prescribing healthcare provider based on the patient's individual needs and response to the medication. It is important to follow the prescribed dosage and administration instructions provided by the healthcare provider.

The safety of MOUNJARO 12.5 mg during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.

To order MOUNJARO 12.5 mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the import paperwork.

MOUNJARO 12.5 mg is a GIP/GLP-1 receptor agonist, which distinguishes it from other classes of antidiabetic medications such as DPP-4 inhibitors, SGLT2 inhibitors, and insulin. Its dual action on GIP and GLP-1 receptors provides a multifaceted approach to glycemic control, which may offer benefits in terms of efficacy and side effect profile compared to other medications.

MOUNJARO 12.5 mg should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. Proper storage and handling are essential to maintain the medication's effectiveness and safety.

MOUNJARO 12.5 mg is administered as a subcutaneous injection using a pre-filled syringe. The injection is typically given once weekly, and the healthcare provider will instruct the patient on the proper administration technique.

The most serious risks associated with MOUNJARO 12.5 mg include acute pancreatitis, severe gastrointestinal adverse reactions, hypersensitivity reactions, tumors in the thyroid, dehydration leading to kidney problems, hypoglycemia, and gallbladder problems. Patients should be monitored for these risks and seek medical attention if any concerning symptoms occur.

MOUNJARO 12.5 mg should not be used by patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not recommended for patients with severe gastroparesis or those who are allergic to tirzepatide or any of the ingredients in MOUNJARO 12.5 mg.